$0.08
17.50%
Nasdaq, Oct 02, 03:39 pm EDT. Closed.
ISIN
US4268971045
Symbol
HEPA

Hepion Pharmaceuticals Inc Stock price

$0.08
+0.01 13.92% 1M
+0.03 47.27% 6M
+0.02 35.00% YTD
+0.02 23.10% 1Y
-228.92 99.96% 3Y
-1,519.92 99.99% 5Y
-610,399.92 100.00% 10Y
-419,999.92 100.00% 20Y
Nasdaq, Closing price Fri, Oct 02 2026
-0.02 19.00%
ISIN
US4268971045
Symbol
HEPA
Industry

Is Hepion Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$8.0m
Enterprise Value
$10.5m
Net debt
-
Cash
-
Shares outstanding
-
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
negative
Financial Health
Equity Ratio
-115.5%
Return on Equity
708.0%
ROCE
-
ROIC
-
Debt/Equity
-
Financials
Revenue | estimate
- | $0.0
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow | ex SBC
- | -
Growth
Revenue | estimate
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
-
FCF per Share
-
Short interest
4.1%
Employees
22
Rev per Employee
$0.0

Hepion Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Hepion Pharmaceuticals Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Hepion Pharmaceuticals Inc forecast:

Buy
86%
Hold
14%

Financial data from Hepion Pharmaceuticals Inc

Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.50 7.50
22% 22%
-
- Research and Development Expense 12 12
67% 67%
-
-19 -19
57% 57%
-
- Depreciation and Amortization 0.03 0.03
57% 57%
-
EBIT (Operating Income) EBIT -19 -19
57% 57%
-
Net Profit -13 -13
73% 73%
-

In millions USD.

Don't miss a Thing! We will send you all news about Hepion Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Hepion Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.

Head office United States
CEO Dr. Lbiati
Employees 22
Founded 2013
Website hepionpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today